Mirum Pharmaceuticals, Inc.
MIRM
$43.45
$0.912.14%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 99.41M | 90.38M | 77.88M | 69.22M | 69.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 99.41M | 90.38M | 77.88M | 69.22M | 69.55M |
| Cost of Revenue | 22.78M | 20.81M | 20.23M | 17.83M | 25.02M |
| Gross Profit | 76.63M | 69.57M | 57.65M | 51.39M | 44.53M |
| SG&A Expenses | 56.83M | 50.55M | 49.21M | 45.64M | 46.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 123.64M | 103.06M | 102.11M | 95.69M | 102.14M |
| Operating Income | -24.22M | -12.68M | -24.23M | -26.47M | -32.59M |
| Income Before Tax | -24.37M | -13.89M | -24.00M | -24.66M | -35.43M |
| Income Tax Expenses | -576.00K | 347.00K | 635.00K | 624.00K | 225.00K |
| Earnings from Continuing Operations | -23.79M | -14.24M | -24.64M | -25.28M | -35.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.79M | -14.24M | -24.64M | -25.28M | -35.66M |
| EBIT | -24.22M | -12.68M | -24.23M | -26.47M | -32.59M |
| EBITDA | -18.17M | -6.63M | -18.38M | -20.80M | -27.09M |
| EPS Basic | -0.50 | -0.30 | -0.52 | -0.54 | -0.87 |
| Normalized Basic EPS | -0.32 | -0.18 | -0.32 | -0.33 | 0.21 |
| EPS Diluted | -0.50 | -0.30 | -0.52 | -0.54 | -0.88 |
| Normalized Diluted EPS | -0.32 | -0.18 | -0.32 | -0.33 | 0.21 |
| Average Basic Shares Outstanding | 47.52M | 47.78M | 47.24M | 46.93M | 40.89M |
| Average Diluted Shares Outstanding | 47.52M | 47.78M | 47.24M | 46.93M | 40.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |